Swiss Re’s Regeneron Pharmaceuticals REGN Stock Holding History

Swiss Re’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	362 +337	+1,348%	+$229K	0.02%	105
2026 Q1	$19.3K	Hold	25	–	–	0.12%	133
2025 Q4	$19.3K	Buy	+25	New	+$17K	﹤0.01%	135

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss Re's REGN Position: Q2 2026 in Review

Swiss Re increased its Regeneron Pharmaceuticals (REGN) stake by 1,348% in Q2 2026, buying an estimated $229K and bringing the position to 362 shares worth $226K. The position accounts for 0.02% of the portfolio, ranked #105.

Swiss Re first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Swiss Re held 362 shares of Regeneron Pharmaceuticals worth $226K as of Q2 2026.
Swiss Re bought 337 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $229K.
Regeneron Pharmaceuticals made up 0.02% of Swiss Re's portfolio in Q2 2026, its #105 holding.
Swiss Re first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.